Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Ireland is an “outlier” in not opposing European Union reforms of the pharmaceutical industry that would potentially damage ...

Pharmacy benefit managers (PBMs) are up to bat in the perpetual blame game between PBMs and the pharmaceutical industry. | ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

On Thursday, 2084 stocks advanced, 1871 declined and 151 remained unchanged on Bombay Stock Exchange with advance decline ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

Where thousands of former Health and Human Services employees will work next is unknown, but biopharma companies likely ...

Aurobindo Pharma's Eugia Pharma approved to manufacture Dasatinib Tablets, a bioequivalent to Bristol-Myers Squibb's Sprycel, ...